Technology & Services: Pharmaceutical-related Studies

Correlogic’s technology has discovered patterns of protein expression indicative of cancer, see, e.g. Lancet 2002; 359(9306):572-7; patterns of gene expression, see, e.g. U.S. Patent 7,096,206 B2; and has been used to accurately distinguish active disease from remission in Wegener’s disease patients, demonstrating its utility for personalized medicine applications, see Arthritis Rheum 2005; 52(3):902-10.

In an experiment designed to test its utility to accelerate the new drug discovery process by detecting drug toxicity before adverse effects become irreversible, Correlogic’s technology was also used to identify patterns in mass spectra from sera that could identify rats treated with the cardiotoxic drug doxorubicin alone from those treated with doxorubicin and a cardioprotectant. See Toxicol Pathol 2004; 32 Suppl 1:122-30.

The early identification, validation or elimination of target molecules could save millions of dollars in the development of a new drug, a new dosing regime or a new application of an existing drug.